E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Caitriona CahirFengmin ZhaoKathy D MillerMin-Jung LeeRichard L PiekarzKaren Lisa SmithUrsa A Brown-GlabermanJennifer S WinnBryan A FallerAdedayo A OnitiloMark E BurkardGeorge T BuddEllis G LevineMelanie E RoycePeter A KaufmanAlexandra ThomasJane B TrepelAntonio C WolffJoseph A SparanoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer.